---
schema_version: "secwatch.filing_event.v1"
accession: "0001601485-25-000114"
form_type: "8-K"
ticker: "ELTX"
cik: "0001601485"
company_name: "Elicio Therapeutics, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:35:17.616394+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Elicio publishes Phase 1 ELI-002 data in Nature Medicine: OS 28.94 months, 77% risk reduction

## Summary
- At 19.7 mo median follow-up, median OS increased to 28.94 months from 16.33 months in Phase 1 AMPLIFY-201.
- Above-threshold T cell responses gave 77% reduction in death risk (HR 0.23) and 88% reduction in relapse risk (HR 0.12).
- 84% (21/25) of patients had tumor biomarker responses; 24% (6/25) achieved complete biomarker clearance.
- Final event-driven DFS analysis for Phase 2 AMPLIFY-7P study of ELI-002 7P in PDAC anticipated Q4 2025.
- ELI-002 was well tolerated; no dose-limiting toxicities or ≥Grade 3 treatment-related adverse events observed.

## SEC filing metadata
- accession: 0001601485-25-000114
- form_type: 8-K
- ticker: ELTX
- cik: 0001601485
- company_name: Elicio Therapeutics, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601485/000160148525000114/0001601485-25-000114-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601485/000160148525000114/angn-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601485-25-000114
- JSON: https://secwatch.observer/filing/0001601485-25-000114.json
- Plain text: https://secwatch.observer/filing/0001601485-25-000114.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.